Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic Polymorphisms

Oxid Med Cell Longev. 2022 Oct 28:2022:5748924. doi: 10.1155/2022/5748924. eCollection 2022.

Abstract

Tardive dyskinesia (TD) is a prevalent movement disorder that significantly impacts patients with schizophrenia (SCZ) due to extended exposure to antipsychotics (AP). Several genetic polymorphisms, including superoxide dismutase (SOD) and DRD3 9ser, have been suggested as explanations why some patients suffer from TD. Methods. A PubMed search was used to search relevant articles using the following keywords: "Tardive Dyskinesia and Superoxide Dismutase". Fifty-eight articles were retrieved. Among them, 16 were included in this review. Results. Overall, 58 studies were retrieved from PubMed. Most studies investigated the association between TD and the SOD-related polymorphisms. In addition, previous studies reported an association between TD occurrence and other genetic polymorphisms. Conclusion. This study found that the risk of TD is associated with altered SOD levels and several genetic polymorphisms, including VAL 66 Met and DRD3 9ser.

Publication types

  • Review

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Humans
  • Polymorphism, Genetic
  • Schizophrenia* / drug therapy
  • Schizophrenia* / genetics
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase / therapeutic use
  • Tardive Dyskinesia* / complications
  • Tardive Dyskinesia* / drug therapy
  • Tardive Dyskinesia* / genetics

Substances

  • Antipsychotic Agents
  • Superoxide Dismutase